{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:24:07Z","timestamp":1726460647909},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.027","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T17:33:33Z","timestamp":1359221613000},"page":"219-222","source":"Crossref","is-referenced-by-count":9,"title":["Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system"],"prefix":"10.1016","volume":"14","author":[{"given":"Carlo","family":"Antozzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.atherosclerosissup.2012.10.027_bib3","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/s10875-010-9401-x","article-title":"Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems","volume":"30","author":"Vincent","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autneu.2008.09.005","article-title":"Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy","volume":"146","author":"Vernino","year":"2009","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00315690","article-title":"A short plasma exchange protocol is effective in severe myasthenia gravis","volume":"238","author":"Antozzi","year":"1991","journal-title":"J Neurol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0955-3886(90)90028-H","article-title":"Therapeutic protein A immunoadsorption. A review","volume":"11","author":"Gjorstrup","year":"1990","journal-title":"Transfus Sci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/039139889401701109","article-title":"Removal of antiacetylcholine receptor antibodies by protein A immunoadsorption in myasthenia gravis","volume":"11","author":"Berta","year":"1994","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(94)90858-3","article-title":"Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis","volume":"343","author":"Antozzi","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1537-2995.1999.39070682.x","article-title":"Clinical evaluation of staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis","volume":"39","author":"Benny","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jca.10023","article-title":"Long-term treatment of myasthenia gravis with immunoadsorption","volume":"17","author":"Haas","year":"2002","journal-title":"J Clin Apher"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1212\/WNL.45.2.338","article-title":"Treatment of myasthenia gravis by immunoadsorption of plasma","volume":"45","author":"Grob","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1749-6632.1988.tb27170.x","article-title":"Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis","volume":"540","author":"Sato","year":"1988","journal-title":"Ann Ny Acad Sci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib15","first-page":"M207","article-title":"Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis for myasthenia gravis","volume":"36","author":"Hosokawa","year":"1990","journal-title":"ASAIO Trans"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib16","first-page":"255","article-title":"Myasthenia gravis (MG) treatment with immunoadsorbent columns","volume":"19","author":"Splendiani","year":"1991","journal-title":"Biomater Artif Immobilization Biotechnol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/adc.69.2.236","article-title":"Immunoadsorption plasmapheresis for severe generalized myasthenia gravis","volume":"69","author":"Ichikawa","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s004150070149","article-title":"Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis","volume":"247","author":"Yeh","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000062987","article-title":"The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis","volume":"48","author":"Munakata","year":"2002","journal-title":"Eur Neurol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00540-005-0335-z","article-title":"Postoperative myasthenic crisis successfully treated with immunoadsorption therapy","volume":"19","author":"Ishizeki","year":"2005","journal-title":"J Anesth"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"Kohler","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0955-3886(97)00102-1","article-title":"Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide","volume":"19","author":"Flachenecker","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1526-0968.1999.00151.x","article-title":"Therapeutic apheresis in myasthenia gravis patients: a six year follow-up","volume":"3","author":"Schneidewind","year":"1999","journal-title":"Ther Apher"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2008.05.026","article-title":"Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients","volume":"201\u2013202","author":"Baggi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.transci.2003.11.005","article-title":"Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis","volume":"30","author":"Ptak","year":"2004","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1525-1594.2006.00268.x","article-title":"Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenia gravis","volume":"30","author":"Zeitler","year":"2006","journal-title":"Artif Organs"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.transci.2011.10.003","article-title":"Experience with extracorporeal elimination therapy in myasthenia gravis","volume":"45","author":"Blaha","year":"2011","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1744-9987.2010.00806.x","article-title":"A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert\u2013Eaton syndrome","volume":"14","author":"Sauter","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib30","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1212\/01.WNL.0000156945.39471.2C","article-title":"Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia","volume":"64","author":"Antozzi","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1034\/j.1600-0404.2000.102004271.x","article-title":"Isaac's syndrome successfully treated by immunoadsorption plasmapheresis","volume":"102","author":"Nakatsuji","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib32","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to KV1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.atherosclerosissup.2012.10.027_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jneuroim.2008.06.020","article-title":"Toward antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis","volume":"201-202","author":"Zisimopoulou","year":"2008","journal-title":"J Neuroimmunol"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T23:00:26Z","timestamp":1562626826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000384"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.027","relation":{},"ISSN":["1567-5688"],"issn-type":[{"type":"print","value":"1567-5688"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}